By consistently dedicating efforts to multi-omic and other high-throughput technologies, it is expected that RNA therapies will have a vital role in future personalized medicine approaches for cancer therapy. Within this framework, analyzing the genetic sequence of a patient's tumor would allow for the detection of crucial driver mutations or changes that cause resistance to drugs. These mutations may then be targeted with RNA therapies that are particularly designed to treat those particular variations. Recent clinical trials have shown that RNA-based therapies hold great potential for treating several illnesses. However, further investigations are required to improve the delivery materials and understand the RNA alterations linked to these groundbreaking drugs, in order to facilitate their integration into clinical practice. Ideally, these therapeutic substances would be specifically administered to the tumor cells of interest using a targeted delivery agent. In this hypothetical situation, the choice of medications for cancer patients would differ depending on the precise abnormalities detected in each person, potentially including inhibitors that target circuits known to cause resistance to treatments. However, doing a more thorough assessment of the challenges and potential benefits discussed in each chapter would enhance the capacity to critically analyze this rapidly evolving field of therapies. This book largely examines the latest developments and clinical studies related to RNA-based medications, while also examining the challenges and future possibilities linked with them. This method shows potential for greatly improving the prognosis of cancer patients.

Les mer
mso-bidi-font-weight: bold;">By consistently dedicating efforts to multi-omic and other high-throughput technologies, it is expected that RNA therapies will have a vital role in future personalized medicine approaches for cancer therapy. Recent clinical trials have shown that RNA-based therapies hold great potential for treating several illnesses.
Les mer

Chapter 1. An Introduction to RNA-based Therapeutics.- Chapter 2. Application Of Advance Crispr/Cas-9 And Other Genomic Tools In RNA Based Therapeutics.- Chapter 3. Applications of Advance ASOs, RNA Mimics and Others in RNA-based Therapeutics.- Chapter 4. Global changes in genome and proteome by mi-RNAs in cancers and other diseases.- Chapter 5. Short- and long-non-coding RNA causes global alterations in the genome and proteome in cancer and other disorders.- Chapter 6. Predictive and Prognostic Relevance of miRNAs in Cancers and Other Diseases.- Chapter 7. Diagnostic, Prognostic, and Predictive Short and Long Non-coding RNA Biomarkers in Cancer.- Chapter 8. RNA-Based Molecular Applications as Tool Compounds in Diagnostic and Clinical Settings.- Chapter 9. Clinical trials on RNA-based therapeutics for the treatment of infectious diseases and other pathologies.- Chapter 10. Challenges and Opportunities Used in RNA-based Therapeutics.- Chapter 11. Pragmatic Clinical Methods, Tools and Amplification techniques used in RNA-based diagnostic applications.- Chapter 12. Practical Clinical Approaches Used in RNA-based Therapeutics.

Les mer

By consistently dedicating efforts to multi-omic and other high-throughput technologies, it is expected that RNA therapies will have a vital role in future personalized medicine approaches for cancer therapy. Within this framework, analyzing the genetic sequence of a patient's tumor would allow for the detection of crucial driver mutations or changes that cause resistance to drugs. These mutations may then be targeted with RNA therapies that are particularly designed to treat those particular variations. Recent clinical trials have shown that RNA-based therapies hold great potential for treating several illnesses. However, further investigations are required to improve the delivery materials and understand the RNA alterations linked to these groundbreaking drugs, in order to facilitate their integration into clinical practice. Ideally, these therapeutic substances would be specifically administered to the tumor cells of interest using a targeted delivery agent. In this hypothetical situation, the choice of medications for cancer patients would differ depending on the precise abnormalities detected in each person, potentially including inhibitors that target circuits known to cause resistance to treatments. However, doing a more thorough assessment of the challenges and potential benefits discussed in each chapter would enhance the capacity to critically analyze this rapidly evolving field of therapies. This book largely examines the latest developments and clinical studies related to RNA-based medications, while also examining the challenges and future possibilities linked with them. This method shows potential for greatly improving the prognosis of cancer patients.

Les mer
Presents fundamentals and advances in the field of RNA biology for cancer therapeutics Discusses RNA therapeutics in gene sequencing for identification of drug resistant mutations Provides both clinical and molecular insights into potential solutions to problems
Les mer
GPSR Compliance The European Union's (EU) General Product Safety Regulation (GPSR) is a set of rules that requires consumer products to be safe and our obligations to ensure this. If you have any concerns about our products you can contact us on ProductSafety@springernature.com. In case Publisher is established outside the EU, the EU authorized representative is: Springer Nature Customer Service Center GmbH Europaplatz 3 69115 Heidelberg, Germany ProductSafety@springernature.com
Les mer

Produktdetaljer

ISBN
9789819634552
Publisert
2025-04-18
Utgiver
Vendor
Springer Nature Switzerland AG
Høyde
235 mm
Bredde
155 mm
Aldersnivå
Research, P, 06
Språk
Product language
Engelsk
Format
Product format
Innbundet

Om bidragsyterne

Dr. Narendra Kumar Sharma

Dr. Narendra Kumar Sharma is working as Assistant Professor at the Department of Biosciences and Biotechnology of the Banasthali Vidyapith, India. He has earlier served as Post-doctoral Fellow at Guangzhou Institutes of Biomedicine and Health (GIBH), Chinese Academy of Sciences (CAS), China and Post-doctoral Fellow at Federal University of Sao Paulo (UNIFESP), Brazil. His research interest is in Genomics and Proteomics with specialization in hypoxia physiology, oxidative stress, post-translational modification, protein biochemistry, signaling pathway, infectious disease and genome editing. He has been conferred with several national and international awards including Young Scientist and Innovation Award. He has served as a referee for a number of international journals. He has also published more than 30 research articles in peer-reviewed international journals and authored or co-authored books and book chapters.

Dr. Tikam Chand Dakal

Dr. Tikam Chand Dakal is presently working as an Assistant Professor at Mohanlal Sukhadia University, Udaipur (Rajasthan). Dr. Dakal is also the State Vice-President of the Microbiologists Society India. Dr. Dakal has been listed among the Top-2% Scientist of the World by Stanford University, USA. Dr. Dakal did his Ph.D. from Italy and has postdoctoral experience from Canada and France. Dr. Dakal has worked as a Senior Scientist at Beckman Research Institute of the City of Hope, California, USA. Dr. Dakal has been conferred with the prestigious FEMS-Young Science Award by FEMS - Germany. Dr. Dakal is also recipient of Best Teacher, Best Researcher and Best Paper awards by prestigious scientific societies. Dr. Dakal is also a member of different academic societies in India and abroad. Dr. Dakal has published more than 80 papers in peer-reviewed journals of international repute and has citations more than 2800 and h-index 20. Dr. Dakal is also serving as Associate Editor, Guest Editor and Review Editor of a number of journals. Dr. Dakal has delivered more than 40 invited lectures and has also been invited as resource person for UGC-HRDC programs and other Government of India sponsored conferences, workshops, seminars etc. Dr. Dakal has also organized a number of International, National conferences, seminars and workshops on different topics. Dr. Dakal is presently working in the field of genome and computational biology and has successfully completed 2 extramural research projects from DST and UGC. 

Prof. Pawan Kumar Maurya

Prof. Pawan Kumar Maurya is Dean, School of Life Long Learning & Head of Department of Biochemistry, Central University of Haryana, India. He has done a PhD from the University of Allahabad (A Central University), India & post-doctoral training from Universidade Federal de Sao Paulo-UNIFESP, Brazil; Taipei Medical University (TMU) and National Taiwan University (NTU), Taiwan. He has more than 14 years of teaching and research experience. He is working on biochemical diagnostics, nanomedicine, and clinical biochemistry. He has published over 92 research articles in reputed publication. He has also edited of 11 books in reputed publication. He is recipient of prestigious fellowships: Science without Borders (Government of Brazil) and National Science Council, Taiwan.

Dr Gulshan Wadhwa

Dr. Gulshan Wadhwa is Presently working as Adviser & Scientist ‘G’ at Department of Biotechnology, Ministry of Science & Technology, New Delhi. The present job profile includes Outreach Division with DBT website, Conference, Travel, Exhibition and Popular Lectures CTEP program dealing with more than 2500 applications every year and supporting more than 600-800 programs in these areas. These programs were initiated and handled by him in 2009. The India International Science Festival, BIO-India, competitive Grant System, Direct benefit transfer and UMANG protocol are the other areas being looked after by him. He is also involved in establishment and coordinate activities of 170 Bioinformatics Centers established at Bioinformatics Division, DBT, including 6 Centers of Excellence in Bioinformatics, 12 DICs and 48 Sub-DICs and the Apex Bioinformatics Centre at DBT, 103 BIF facilities, 6 Graphics Facilities, 6 M.Sc./M.Tech. programmes/Advanced Diploma courses in Bioinformatics at various locations all over the country and a Super Computing Facility at IIT Delhi. Financial support and physical monitoring of the Programme, centers and more than 200 R&D projects in Bioinformatics. Dr Wadhwa is also worked for International Cooperation with South American Countries. MoU has been signed with 3 countries viz. Brazil, Cuba and Costa Rica and collaborative projects are being supported, Animal Biotechnology and Aquaculture, National and International Exhibitions, State Partnership Programme with Madhya Pradesh, Direct Benefit Transfer scheme of the Department, Umang Portal.